Nabriva Therapeutics (Nabriva Therapeutics) Price-to-Funds-From-Operations : (As of May. 15, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Price-to-Funds-From-Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Executives

Hogan H Michael Iii	officer: Chief Executive Officer	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio	officer: Chief Financial Officer	15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan	director
Broom Colin Md	officer: Chief Executive Officer	119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow	officer: Director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder	officer: Chief Executive Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger	officer: General Counsel and Corp Sec	633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia	officer: Chief Medical Officer	C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan	officer: Chief Financial Officer	C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino	officer: Chief Commercial Officer	1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty	officer: General Counsel & Corp Sec.	1301 2ND AVE, SEATTLE WA 98101